Head-to-head evidence
Alirocumab vs Inclisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals
NCT01507831 · Phase 3 · completed
The study was large (2,341 participants), randomized, quadruple-blind, and placebo-controlled. Its primary clinical safety endpoint was reported, but the registry does not provide a statistical significance test for the comparison, so whether the primary endpoint was met cannot be determined.
Next expected readout: December 2026 · NCT07477704 (registry estimate)
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT03397121 · Phase 3 · completed
The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.
Next expected readout: October 2026 · NCT05360446 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Inclisiran's landscape